Novel Agent May Benefit Men with Metastatic HRPC
CHICAGO – A new compound that specifically inhibits production of the cell-survival protein clusterin appears to be well tolerated and produces PSA responses when given in combination with docetaxel and prednisone in men with metastatic hormone refractory prostate cancer (HRPC), a study found.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.